0000000000176502
AUTHOR
Orlando A
Trapianto di midollo nel Crohn
Tofacitinib in active ulcerative colitis
Fatal necrotising fasciitis associated with intramuscolar injection of non steroidal anti-inflammatory drugs after uncomplicated endoscopic polipectomy
NOD2/CARD15,and intestinal permeability in patients,first degree relatives and controls in high incidence area of Crohn's disease.
Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study
Remarkable differences in quality of care (QoC) might be observed in different countries, affecting quality of life of inflammatory bowel disease (IBD) patients. The aim of this study was to assess patient and physician perceptions of the QoC in Italy.A multicentre observational study on the quality of care in IBD (SOLUTION-1) was conducted in 36 IG-IBD (Italian Group for Inflammatory Bowel Disease) centres in Italy. The QUOTE-IBD (Quality of Care Through the Patient's Eyes) questionnaire was administered to IBD patients and to the attending physicians. The Quality Impact (QI) score summarises the QUOTE-IBD questionnaire, and a QI9 is considered satisfactory.Nine-hundred-ninety-two patients…
Radiofrequency thermal ablation vs percutaneous ethanol injection for small hcc in cirrhosis:metanalysis of randomized controlled trials
1. Am J Gastroenterol. 2009 Feb;104(2):514-24. Epub 2009 Jan 13. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Department of Medicine, Pneumology and Nutrition Clinic, V. Cervello Hospital, University of Palermo, Piazza Mameli 1, Palermo, Italy. ambrogiorlando@tiscali.it OBJECTIVES: Radiofrequency thermal ablation (RF) and percutaneous ethanol injection (PEI) have been employed in the treatment of small hepatocellular carcinoma (HCC) as curative treatments. The aim of the study was to review the available evidence compari…
NEWLY DIAGNOSED NEOPLASIA IN CROHN DISESE PATIENTS TREATED WITH INFLIXIMAB;A 1 YEAR LONGER FOLLOW UP FROM A MULTICENTER MATCHED PAIR STUDY
1. Inflamm Bowel Dis. 2011 Mar;17(3):758-66. doi: 10.1002/ibd.21416. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F, Papi C, Meucci G, Riegler G, Sica G, Rizzello F, Mocciaro F, Onali S, Calabrese E, Cottone M, Pallone F. GI Unit, University, Tor Vergata, Roma. biancone@med.uniroma2.it BACKGROUND: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased f…
NOD2/CARD15 mutations and ontestinal permeability in pts,first degree relatives and controls in a high incidence area of Crohn's disease
Calprotectin in the prediction of endoscopic post-surgical recurrence in CD
Gastrointestinal lesions associated with spondyloarthropathies.
PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION 8 RFTA) OF SMALL HEPATOCELLUALR CARCINOMA: A PROSPECTIVE STUDY
PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION 8 RFTA) OF SMALL HEPATOCELLUALR CARCINOMA: A PROSPECTIVE STUDY Data: 2004 Dettaglio tipologia d'Ateneo: 3a - Articoli su riviste ISI (anche on line)
Percutaneous radiofrequency therma ablation of small hepatocellular carcinoma: a prospective study
Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study
Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX…
NOD1/CARD15,TLR4 and intestinal permeability in pts,first degree relatives and controls in a high incidence area of CD
Infliximab in the treatment of steroid resistant dependant and fistulating crohn's disease:an analysis of predictors of response in an italian multicenter open study in 573 pts
Long term follow-up in an incident cohort of 583 pts with CD
Severe acute colitis associated with citomegalovirus
Comparing medical treatment in Crohn's disease
The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…